TORONTO and HAIFA, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce that its Chief Executive Officer, Dr. Lior Shaltiel, has been invited to speak at the upcoming Bioprocess International Conference being held from September 23 – 26 in Boston, MA. NurExone’s participation in this event highlights the Company’s leadership role in the field of exosomes for clinical applications and regenerative medicine. Dr. Shaltiel will showcase the Company’s promising ExoPTEN nanodrug, a potential treatment for acute spinal cord injuries and other central nervous system indications, such as glaucoma care.
Dr. Shaltiel’s presentation will focus on “A Comparative Analysis of AbbVie and NurExone’s approaches to Effective Spinal Cord Injury Treatment”. This conference is a significant global event in bioprocessing and manufacturing, and an opportunity to engage with collaboration partners, industry leaders, researchers, and innovators.